Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

clementmoll63 Jan. 11 at 2:23 PM

💊 Pharma Analyst Moves – Jan 10, 2026 $BIIB 📈 Big target raises across the board • Truist: $142 → $190 • Goldman: $197 → $225 • Mizuho: $177 → $207 $ABBV ⚖️ Mixed signals • Wolfe: Outperform → Peer Perform • UBS stays Neutral, PT $220 → $240 $AZN 🟢 Berenberg reiterates Buy, PT $95 $GSK 🟢 Jefferies reiterates Buy, PT $55.60 $AMRX 📈 Truist PT $14 → $15 Plenty of action in pharma today—watching how price reacts to these revisions. 👀📊 https://x.com/Theresa40319009/status/2008802936814776503

0 · Reply

WaverVanir Jan. 11 at 1:59 PM

$ABBV Bearish setup developing 🐻 Multiple CHoCH signals at the premium zone ($226-243). Price rejected weak high and now testing key levels: ⚠️ Breaks $216 → confirms breakdown 🎯 Target: Equilibrium at $204.02 Structure: Premium zone rejection ✓ Lower highs forming after Oct peak RSI rolling over (51) — momentum fading Strong low sits at $170 if equilibrium fails to hold. VolanX flagged: PUT 75% conf | $223.93 → $211.35 target — WaverVanir International

0 · Reply

beeelaaal Jan. 11 at 1:44 PM

$VSTM $ABBV or $AMGN

0 · Reply

WaverVanir Jan. 11 at 1:41 PM

VolanX SWING scan complete ⚡ 34 signals found across market Top hits: 📈 $MELI — CALL 75% conf | Entry $2187 → Target $2375 | 1.5 R:R | 58% win 📈 $OTIS — CALL 75% | $89.89 → $93.62 | 1.5 R:R | 58% win 📉 $ABBV — PUT 75% | $223.93 → $211.35 | 1.5 R:R | 58% win 📈 $FXI — CALL 75% | $39.91 → $41.64 | 1.5 R:R | 58% win 📈 $CRWD — CALL 75% | $458.32 → $484.44 | 1.5 R:R | 66% win 28 CALLs | 6 PUTs | 21 high confidence (≥70%) | Avg conf: 70.1% Q/A welcome 👇 https://youtu.be/h_TjDA-zyfo?si=oMeLxwKZrtPM301B

0 · Reply

Gps_100X_ROI_Potential Jan. 11 at 10:44 AM

$SLS $ABBV $BMY $RHHBY

0 · Reply

WallStreetBuyDip Jan. 11 at 4:53 AM

$PFE trading at $25 with volume 33% below average, while $ABBV sitting at $220 with 6% above average volume. ABBV showing strength with a higher price level and increased volume - seems like a solid Healthcare sector play! Will these trends continue in the sector?

0 · Reply

Ashte Jan. 10 at 7:02 PM

$XLV $LLY $UNH $ISRG $ABBV

0 · Reply

JacoI3 Jan. 10 at 12:43 AM

$NVO Nobody takes advantage of America like America $LLY $ABBV $AMGN $MRK

1 · Reply

TechTraderGrok Jan. 9 at 9:05 PM

Sold $ABBV at $220.48 (-4.1%). From Grok: "Recent acquisition denial + slashed EPS guidance on $1.3B R&D charge triggered pullback to $220S; exit long to lock small gain/loss protection pre-earnings volatility." https://www.techtrader.ai/grokwall/?post=16055&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

MoneyGroupLLC Jan. 9 at 9:04 PM

Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 30 2026 Buy in Price: $6.43 - $6.75 Sell Price: $11.06 Profit : +72% (Turn every $1 into $1.72) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 3 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 3 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 4 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 4 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 4 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 5 days ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 5 days ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 6 days ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 7 days ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 8 days ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 9 days ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 11 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 14 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 23 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 24 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 25 days ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 27 days ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 4 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 4 weeks ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 5 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 5 weeks ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 5 weeks ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Nov 29, 2025, 8:02 AM EST - 6 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

Nov 28, 2025, 7:01 AM EST - 6 weeks ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 25, 2025, 9:30 AM EST - 6 weeks ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 6 weeks ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 7 weeks ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 9:00 AM EST - 7 weeks ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Nov 18, 2025, 8:25 AM EST - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

Nov 14, 2025, 4:31 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 3:19 PM EST - 2 months ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

Nov 13, 2025, 8:30 AM EST - 2 months ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 12, 2025, 3:06 PM EST - 2 months ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 8:30 AM EST - 2 months ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 11, 2025, 10:40 PM EST - 2 months ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 8, 2025, 6:38 AM EST - 2 months ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Nov 3, 2025, 9:58 AM EST - 2 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

Nov 1, 2025, 11:15 PM EDT - 2 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Nov 1, 2025, 10:25 AM EDT - 2 months ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

Oct 31, 2025, 3:56 PM EDT - 2 months ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 11:47 AM EDT - 2 months ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 10:39 AM EDT - 2 months ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 8:42 AM EDT - 2 months ago

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:20 AM EDT - 2 months ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 7:54 AM EDT - 2 months ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:49 AM EDT - 2 months ago

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 29, 2025, 5:00 PM EDT - 2 months ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 8:11 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

clementmoll63 Jan. 11 at 2:23 PM

0 · Reply

WaverVanir Jan. 11 at 1:59 PM

0 · Reply

beeelaaal Jan. 11 at 1:44 PM

$VSTM $ABBV or $AMGN

0 · Reply

WaverVanir Jan. 11 at 1:41 PM

0 · Reply

Gps_100X_ROI_Potential Jan. 11 at 10:44 AM

$SLS $ABBV $BMY $RHHBY

0 · Reply

WallStreetBuyDip Jan. 11 at 4:53 AM

0 · Reply

Ashte Jan. 10 at 7:02 PM

$XLV $LLY $UNH $ISRG $ABBV

0 · Reply

JacoI3 Jan. 10 at 12:43 AM

$NVO Nobody takes advantage of America like America $LLY $ABBV $AMGN $MRK

1 · Reply

TechTraderGrok Jan. 9 at 9:05 PM

0 · Reply

MoneyGroupLLC Jan. 9 at 9:04 PM

0 · Reply

V9RDPUMA Jan. 9 at 8:31 PM

$ABBV WTF happened now???

0 · Reply

Czreri1 Jan. 9 at 8:13 PM

$ABBV I absolutely hate this stock. How they can’t be held responsible for the WSJ article and manipulation is suspicious.

0 · Reply

dogDazeSummer Jan. 9 at 7:51 PM

$MLTX Clinical Data Risk has been removed. Regulatory risk has been eliminated/ reduced. 13% of float is short. An astounding 5m shares caught off guard w good insider ownership. Watch for Monday open $22.50 with no news (more if Merck had arrangement to close upon positive FDA meeting). All parties in town for $JPM Sunday night. This entity is more valuable than late 2024. Between $MRK or $ABBV takeout of $35-$45 is very realistic. Don’t be surprised to see bidding war now that facts & path are clear. Wedbush: “good likelihood of approval” Moonlake is 1/3 cost at 52 week high and in better position than **any other prior date in company history**.

0 · Reply

dogDazeSummer Jan. 9 at 6:50 PM

After the completely de-risking of $MLTX in HS (now green light to submit FDA approval), does $MRK re ignite their 2024 offer $4B next week? Same question on $IFRX CRUSHING P2 in HS. Does $RHHBY or $ABBV seal a deal next week? Allowing Moonlake to disregard a high placebo study is a great sign for Inflarx PS /CSU/HS. Safety non issue. Moonlake more valuable today vs November at $55; Inflarx more valuable & further along than 4x value.

3 · Reply

Capitulation_0 Jan. 9 at 6:42 PM

$RVMD $ABBV saying they're not bidding may have save $MRK 7B ish. Bid 24B and use the 6B to buy 1 or more assets. ARDX can be had for 4B. IMCR for 3B

0 · Reply

Oldpuck Jan. 9 at 5:08 PM

$ABBV Some people will never get over Humira

0 · Reply

_JAKE Jan. 9 at 3:00 PM

$IMRX Holding my shares long term. Will keep buying if it stays this low. No stop loss or margin here, no one is getting my shares except maybe $ABBV or other big Pharm if they by us out 😀

0 · Reply

HerbertSowell1052 Jan. 9 at 1:18 PM

$ABBV defensive rotation plus yield makes this an easy hold in this tape

1 · Reply

ZacksResearch Jan. 9 at 12:45 PM

All eyes on $ABBV’s immunology numbers this quarter — this is the real swing factor. 👀💊 The Q4 outlook hinges on **surging Skyrizi and Rinvoq demand**, as investors look for immunology sales to **offset Humira’s past loss of exclusivity**. Can immunology fully carry the torch? Full outlook here 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-teaser-28139&ADID=SYND_STOCKTWITS_TWEET_2_2814783_TEASER_28139

0 · Reply

ZacksResearch Jan. 9 at 11:45 AM

$ABBV's Skyrizi & Rinvoq driving potential Q4 growth! 🌟 💊 Skyrizi & Rinvoq sales projected at $4.87B and $2.33B, respectively, aiding AbbVie's top-line growth despite Humira's exclusivity loss. 📈 Trading at a P/E of 15.50x, below the industry average of 17.91x, offers valuation appeal. Learn about ABBV's growth potential this year 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-body-28138&ADID=SYND_STOCKTWITS_TWEET_2_2814783_BODY_28138

0 · Reply

Dubbyy Jan. 9 at 6:28 AM

$ABBV Pick one please either $CAPR or $SLS

1 · Reply

JInvestTrade Jan. 9 at 4:13 AM

More accurate than $DXCM and $ABBV and it works for 1 year. $SENS, $PODD, $TNDM. https://www.linkedin.com/posts/gingervieira_you-ask-hows-the-accuracy-on-the-eversense-activity-7413296265230458880-6FRr?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=share_via

2 · Reply

Market Cap	388.97B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	23.72
Forward PE	15.55
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	6,714,100
Avg Vol	6,024,820
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	12%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.44